MARKET

ADVM

ADVM

Adverum
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.49
-0.21
-1.96%
Closed 16:32 12/12 EST
OPEN
10.70
PREV CLOSE
10.70
HIGH
10.86
LOW
10.02
VOLUME
1.06M
TURNOVER
--
52 WEEK HIGH
16.38
52 WEEK LOW
2.810
MARKET CAP
677.53M
P/E (TTM)
-10.8942
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ADVM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ADVM News

  • Shareholder Alert - Adverum Biotechnologies - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
  • GlobeNewswire.12/02 15:53
  • 3 Soaring Biotech Stocks to Watch in December
  • MotleyFool.com.12/02 12:31
  • Announcing: Adverum Biotechnologies (NASDAQ:ADVM) Stock Increased An Energizing 264% In The Last Three Years
  • Simply Wall St..12/02 12:28
  • Timing the Market, Is it Possible? - November 25, 2019
  • Zacks.11/25 13:56

More

Industry

Biotechnology & Medical Research
+0.57%
Pharmaceuticals & Medical Research
+0.73%

Hot Stocks

Name
Price
%Change

About ADVM

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing, specifically in process development and assay development.
More

Webull offers Adverum Biotechnologies Inc (ADVM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.